Please find attached the Q1 FY 27 Financial Results
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 04 Aug 2026, 01:43 PM IST · BSE ID: 309418af-3dab-435e-bd5b-0c85cfb70b20
View Original BSE Filing (PDF)
💡
In Simple Terms
Morepen Laboratories reported strong Q1 FY27 profits and revenue, while also making key decisions about its Medical Devices business and leadership.
🤖 AI Summary
- Consolidated Net Profit for Q1 FY27 stood at Rs. 5634.58 Lakhs, compared to Rs. 1140.66 Lakhs in Q1 FY26.
- Revenue from operations reached Rs. 57012.81 Lakhs for Q1 FY27, against Rs. 42523.88 Lakhs in Q1 FY26.
- The Board approved an extension for hiving off the Medical Devices Business to Morepen Medipath Limited.
- Mr. Sushil Suri's re-appointment as Chairman & Managing Director for three years, effective October 20, 2026, was approved.
- A record date of September 19, 2026, was set for determining eligibility for the final dividend for FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Net Profit (Q1 FY27)
5634.58 Lakhs
393.97%
Consolidated Revenue from Operations (Q1 FY27)
57012.81 Lakhs
34.07%
Basic & Diluted EPS (Q1 FY27)
1.03 Rs.
415.00%
🏢 How This Affects the Company
The hiving off of the Medical Devices Business into a subsidiary, Morepen Medipath Limited, indicates a strategic focus on specialized segments, potentially streamlining operations. The sustained growth in revenue from operations suggests robust demand in its pharmaceutical business.
The significant increase in net profit for Q1 FY27 by Rs. 4493.92 Lakhs indicates improved profitability compared to the prior year. The extension for hiving off the Medical Devices business could impact future financial reporting structure.
The re-appointment of Mr. Sushil Suri ensures continuity in leadership for three additional years, maintaining strategic direction. The hiving off of the Medical Devices business suggests potential operational restructuring within that segment.
The re-appointment of key management provides stability, potentially reducing leadership transition risks. The extension of the timeline for the Medical Devices business hive-off implies ongoing execution, subject to member approval.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must hold shares by September 19, 2026, to be eligible for the final dividend for FY26.
👤
Who Is Affected
Shareholders of record as of September 19, 2026, will be eligible for the final dividend for the financial year ended March 31, 2026, if approved at the 41st AGM.
🔍
Management Signal
Management intends to maintain leadership stability by proposing Mr. Sushil Suri's re-appointment and to pursue strategic restructuring of the Medical Devices Business.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Approval of final dividend at the 41st Annual General Meeting on September 26, 2026.
Completion and operational details of hiving off Medical Devices Business into Morepen Medipath Limited.
Outcome of member approval for re-appointment of Mr. Sushil Suri as Chairman & Managing Director.
LOW RISK
No new significant risks identified; leadership continuity and strategic plans indicate stability.
💡 Investor Takeaway
Morepen Laboratories Ltd reported Q1 FY27 consolidated net profit of Rs. 5634.58 Lakhs, a 393.97% increase from Rs. 1140.66 Lakhs in Q1 FY26. Revenue from operations rose 34.07% to Rs. 57012.81 Lakhs from Rs. 42523.88 Lakhs. The Board set September 19, 2026, as the record date for the FY26 final dividend.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Net Profit for Q1 FY27 increased to Rs. 5634.58 Lakhs, up from Rs. 1140.66 Lakhs in Q1 FY26.
- Consolidated Revenue from operations for Q1 FY27 grew to Rs. 57012.81 Lakhs, from Rs. 42523.88 Lakhs in Q1 FY26.
⚠️ Concerns
- Purchases of stock-in-trade decreased to Rs. 964.09 Lakhs in Q1 FY27 from Rs. 1703.99 Lakhs in Q1 FY26.
- Other Expenses were Rs. 3467.94 Lakhs in Q1 FY27, compared to Rs. 3632.31 Lakhs in Q1 FY26.
📅 Company Track Record
Morepen Laboratories Ltd reported a net profit of Rs. 5634.58 Lakhs in Q1 FY27, following a net profit surge to Rs. 5634.58 Lakhs as reported for Q1 FY27 in an earlier filing on August 04, 2026. The Board meeting on May 22, 2026, was to approve Q4 and FY26 financial results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Morepen Laboratories Ltd's consolidated net profit in Q1 FY27?
Morepen Laboratories Ltd reported a consolidated net profit of Rs. 5634.58 Lakhs for the quarter ended June 30, 2026.
What was Morepen Laboratories Ltd's consolidated revenue from operations in Q1 FY27?
Consolidated revenue from operations for Morepen Laboratories Ltd in Q1 FY27 was Rs. 57012.81 Lakhs.
When is the record date for Morepen Laboratories Ltd's final dividend for FY26?
The record date for determining members eligible to receive the final dividend for the financial year ended March 31, 2026, is Saturday, September 19, 2026.
What decision was made regarding the Medical Devices Business of Morepen Laboratories Ltd?
The Board approved the extension of the timeline for hiving off the Medical Devices Business into Morepen Medipath Limited, a subsidiary company, on a slump sale basis.
Who was re-appointed as Chairman & Managing Director of Morepen Laboratories Ltd?
Mr. Sushil Suri was re-appointed as the Chairman & Managing Director of Morepen Laboratories Ltd for a further period of three years, effective from October 20, 2026, to October 19, 2029.
Questions based on this BSE filing only. For information purposes.